Allergan’s Oxymetazoline based cream, Rhofade (oxymetazoline hydrochloride cream 1%) – for the treatment of the redness of rosacea is now generally available. Does it work to effectively and safely reduce the redness of rosacea? You have come to the right page to find out.
Some Oxymetazoline History
For rosacea sufferers it has been a long development cycle, the story starting with the emergence of Oxymetazoline as a rosacea active in 2007. Aspect Pharmaceuticals, Vicept Therapeutics and finally Allergan were owners of the intellectual property behind Rhofade, which first came to our attention through a 2005 patent (20050165079) by Shanler and Ondo.
So it has been a very long time since rosacea sufferers first starting hearing about the active in products like Afrin being a possible treatment for the redness of rosacea.
What is Rhofade?
Rhofade is being promoted as ;
The first and only α 1A adrenoceptor agonist approved for persistent facial erythema associated with rosacea in adults.
This is sales-speak as Mirvaso has been available for several years now and is similarly promoted as the only `α adrenoceptor agonist’.
Is Rhofade the same as Mirvaso?
If you were to solely read internet reviews of Mirvaso you could be forgiven for thinking that Mirvaso has been a very problematic product for Galderma (see Mirvaso Reviews). The adverse reaction rate to Mirvaso during the clinical trials before approval does not appear to be borne out by subsequent internet respondents. It isn’t clear why this appears to be the case – more frequent adverse reactions experienced outside the tightly controlled and monitored environment of the blinded clinical trials.
Every rosacea sufferer looking for relief from their red face is hoping that as claimed, Rhofade really will prove to be a “topical treatment of persistent facial erythema associated with rosacea in adults.”
Rhofade – the successor to Mirvaso?
It isn’t yet clear what Allergan have been able to do with the commonly available active ingredient Oxymetazoline to package it as palatable to the sensitive skin of rosacea sufferers. One clue appears to be the usage of “more selective for α1D-adrenoceptors are less prone to induce receptor desensitization than are α1A– or α1B-agonists” as found in the off the shelf products”. Although we know now that Rhofade is being promoted as a α 1A adrenoceptor agonist.
Certainly we are all hoping that Rhofade will become a well liked and tolerated rosacea treatment, that is true to the 1 year, only 3% adverse reaction rate generally experienced during the Rhofade clinical trials.
How much improvement will I see?
It is worth tempering your hopes for success with Rhofade with the published clinical trial data that shows that ;
Going on the published clinical data, basically one in 6 or 7 users of RHOFADE will have a 2-grade improvement in their facial redness, typically for 12 hours, and continuing for 29 once-daily uses.
So finally, rosacea sufferers are able to fill a prescription for Rhofade. Please let your fellow rosacea sufferes know what you think of Rhofade, we are especially interested in any rebound redness that your might experiences.
Please leave a comment below. Thanks!